BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 30706129)

  • 1. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
    Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
    Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.
    Rao Q; Liu B; Cheng L; Zhu Y; Shi QL; Wu B; Jiang SJ; Wang Y; Wang X; Yu B; Zhang RS; Ma HH; Lu ZF; Tu P; Wang JD; Zhou XJ
    Am J Surg Pathol; 2012 Sep; 36(9):1327-38. PubMed ID: 22895266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
    Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
    Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
    Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
    Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translocation carcinomas of the kidney.
    Argani P
    Genes Chromosomes Cancer; 2022 May; 61(5):219-227. PubMed ID: 34704642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from 801 clinical TFE3/TFEB fluorescence in situ hybridization assays performed on renal cell carcinoma suspicious for MiTF family aberrations.
    Wang XM; Shao L; Xiao H; Myers JL; Pantanowitz L; Skala SL; Udager AM; Vaishampayan U; Mannan R; Dhanasekaran SM; Chinnaiyan AM; Betz BL; Brown N; Mehra R
    Am J Clin Pathol; 2023 Dec; 160(6):549-554. PubMed ID: 37499055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity.
    Argani P; Reuter VE; Zhang L; Sung YS; Ning Y; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Nov; 40(11):1484-1495. PubMed ID: 27565001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [TFEB-amplified renal cell carcinoma. A case report and review of the literature].
    Mayoral Guisado C; Gómez Durán Á; Agustín Benítez López D; Toro Zambrano W; Rubio Fernández A; Moreno Ontalba A; Díaz Delgado M
    Rev Esp Patol; 2018; 51(4):248-252. PubMed ID: 30269777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations.
    Gupta S; Argani P; Jungbluth AA; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Sanchez A; Hakimi AA; Mcfarlane T; Salazar PA; Williamson SR; Skala SL; Mehra R; Hes O; Antonescu CR; Ladanyi M; Arcila ME; Reuter VE
    Am J Surg Pathol; 2019 Nov; 43(11):1445-1461. PubMed ID: 31600176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.
    Harada S; Caliò A; Janowski KM; Morlote D; Rodriguez Pena MD; Canete-Portillo S; Harbi D; DeFrank G; Magi-Galluzzi C; Netto GJ; Martignoni G; Mackinnon AC
    Mod Pathol; 2021 Nov; 34(11):2055-2063. PubMed ID: 34148064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.
    Argani P; Laé M; Hutchinson B; Reuter VE; Collins MH; Perentesis J; Tomaszewski JE; Brooks JS; Acs G; Bridge JA; Vargas SO; Davis IJ; Fisher DE; Ladanyi M
    Am J Surg Pathol; 2005 Feb; 29(2):230-40. PubMed ID: 15644781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanotic MiT family translocation neoplasms: Expanding the clinical and molecular spectrum of this unique entity of tumors.
    Saleeb RM; Srigley JR; Sweet J; Doucet C; Royal V; Chen YB; Brimo F; Evans A
    Pathol Res Pract; 2017 Nov; 213(11):1412-1418. PubMed ID: 28969862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcomatoid renal cell tumor harboring a novel BYSL::TFEB fusion with concurrent TFEB amplification.
    Lin R; Flerova E; Wamsley CE; McCue PA; Lallas CD; Jiang W; Huang J; Wang ZX; Li L
    Genes Chromosomes Cancer; 2023 Jun; 62(6):353-360. PubMed ID: 36704911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The translocation carcinoma: A pediatric renal tumor also in adults].
    Bruder E; Moch H
    Pathologe; 2016 Mar; 37(2):159-65. PubMed ID: 26972595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
    Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic and Molecular Analysis of the TFEB Fusion Variant Reveals New Members of TFEB Translocation Renal Cell Carcinomas (RCCs): Expanding the Genomic Spectrum.
    Xia QY; Wang XT; Fang R; Wang Z; Zhao M; Chen H; Chen N; Teng XD; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Am J Surg Pathol; 2020 Apr; 44(4):477-489. PubMed ID: 31764220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
    Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translocation renal cell carcinomas in adults: a single-institution experience.
    Zhong M; De Angelo P; Osborne L; Paniz-Mondolfi AE; Geller M; Yang Y; Linehan WM; Merino MJ; Cordon-Cardo C; Cai D
    Am J Surg Pathol; 2012 May; 36(5):654-62. PubMed ID: 22446944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasms.
    Caliò A; Marletta S; Brunelli M; Pedron S; Portillo SC; Segala D; Bariani E; Gobbo S; Netto G; Martignoni G
    Virchows Arch; 2022 Dec; 481(6):877-891. PubMed ID: 35980471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.